Clinical Trial Detail

NCT ID NCT02425891
Title A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

triple-receptor negative breast cancer

Therapies

Nab-paclitaxel

Atezolizumab

Age Groups: adult

Additional content available in CKB BOOST